Due to the critical role played by CXCR4 in HIV infection and tumor progression, there has been considerable interest in developing specific CXCR4 antagonists, a number of which are in the clinical development pipeline (Kuhne et al., 2013; www.clinicaltrials.gov). The gene discussed is CXCR4; the disease is HIV infectious disease.